Related references
Note: Only part of the references are listed.Systematic or Meta-analysis Studies Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis
Alberto Martini et al.
CANCER TREATMENT REVIEWS (2022)
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
Joaquim Bellmunt et al.
LANCET ONCOLOGY (2021)
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma
D. F. Bajorin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
The natural history of untreated muscle-invasive bladder cancer
Alberto Martini et al.
BJU INTERNATIONAL (2020)
Restricted Mean Survival Times to Improve Communication of Evidence from Cancer Randomized Trials and Observational Studies
Ludovic Trinquart et al.
EUROPEAN UROLOGY (2019)
Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer
Alberto Martini et al.
CANCER (2019)
Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis
Scot A. Niglio et al.
EUROPEAN UROLOGY (2019)
Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer
Andrea B. Apolo et al.
JAMA ONCOLOGY (2019)
Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio
Kyongsun Pak et al.
JAMA ONCOLOGY (2017)
Restricted Mean Survival Time as a Measure to Interpret Clinical Trial Results
Dae Hyun Kim et al.
JAMA CARDIOLOGY (2017)
Measuring differential treatment benefit across marker specific subgroups: The choice of outcome scale
Jaya M. Satagopan et al.
CONTEMPORARY CLINICAL TRIALS (2017)
Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies
Hajime Uno et al.
ANNALS OF INTERNAL MEDICINE (2015)
Impact of Informative Censoring on the Kaplan-Meier Estimate of Progression-Free Survival in Phase II Clinical Trials
Federico Campigotto et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis
Hajime Uno et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
Patricia Guyot et al.
BMC MEDICAL RESEARCH METHODOLOGY (2012)
Presalvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy
Philippe E. Spiess et al.
CANCER (2006)
Regression analysis of restricted mean survival time based on pseudo-observations
PK Andersen et al.
LIFETIME DATA ANALYSIS (2004)
Share Paper
